| Literature DB >> 27689727 |
Silvia Franchini1, Leda Ivanova Manasieva1, Claudia Sorbi1, Umberto M Battisti1, Paola Fossa2, Elena Cichero2, Nunzio Denora3, Rosa Maria Iacobazzi4, Antonio Cilia5, Lorenza Pirona5, Simone Ronsisvalle6, Giuseppina Aricò6, Livio Brasili7.
Abstract
Recently, 1-(1,4-dioxaspiro[4,5]dec-2-ylmethyl)-4-(2-methoxyphenyl)piperazine (1) was reported as a potent 5-HT1AR agonist with a moderate 5-HT1AR selectivity. In an extension of this work a series of derivatives of 1, obtained by combining different heterocyclic rings with a more flexible amine chain, was synthesized and tested for binding affinity and activity at 5-HT1AR and α1 adrenoceptors. The results led to the identification of 14 and 15 as novel 5-HT1AR partial agonists, the first being outstanding for selectivity (5-HT1A/α1d = 80), the latter for potency (pD2 = 9.58) and efficacy (Emax = 74%). Theoretical studies of ADME properties shows a good profile for the entire series and MDCKII-MDR1 cells permeability data predict a good BBB permeability of compound 15, which possess a promising neuroprotective activity. Furthermore, in mouse formalin test, compound 15 shows a potent antinociceptive activity suggesting a new strategy for pain control. Copyright ÂEntities:
Keywords: 5-HT1A receptor; Agonist; Analgesic activity; BBB penetration; Neuroprotection
Mesh:
Substances:
Year: 2016 PMID: 27689727 DOI: 10.1016/j.ejmech.2016.09.050
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514